Product Code: POCT MT-RNR1 25
From £1300.00
Registration closed: 07/07/2025
Applicable to all labs undertaking point-of-care molecular testing of MT-RNR1 for avoidance of aminoglyocside induced hearling loss in neonates.
PCR based
Not applicable
Artificial Buccal Swab
No
The scheme is designed to assess the analytical process (genotyping) only.
The user will receive will a survey report containing device specific performance data benchmarked against the cohort of participating users. Additionally a annual report summarising the years data will be provided.
Users will receive three EQA samples every two months (18 samples per year), allowing them to verify the ongoing accuracy of MT-RNR1 testing on their POCT devices, to ensure patients receive the most reliable diagnoses possible.
No restrictions on number of participants. Open to laboratories from ALL countries (note: some restrictions may apply*)
*Sanctions, delivery network exceptions, restrictions on importation etc.
added wishlist!
View Wishlist
View Wishlist
Express your interest in ''.